Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BLCO
stocks logo

BLCO

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
1.25B
+3.1%
0.109
-16.38%
1.27B
+6.09%
0.182
+6.8%
1.37B
+6.83%
0.293
+17.18%
Estimates Revision
The market is revising Upward the revenue expectations for Bausch + Lomb Corporation (BLCO) for FY2025, with the revenue forecasts being adjusted by 0.63% over the past three months. During the same period, the stock price has changed by 17.68%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.63%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-28.7%
In Past 3 Month
Stock Price
Go Up
up Image
+17.68%
In Past 3 Month
9 Analyst Rating
down Image0
Wall Street analysts forecast BLCO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLCO is 13.38 USD with a low forecast of 11.00 USD and a high forecast of 17.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
6 Hold
1 Sell
Hold
down Image0
Current: 14.180
sliders
Low
11.00
Averages
13.38
High
17.00
down Image0
Current: 14.180
sliders
Low
11.00
Averages
13.38
High
17.00
Citi
Neutral
maintain
$13 -> $15
2025-07-09
Reason
Citi
Price Target
$13 -> $15
2025-07-09
maintain
Neutral
Reason
Citi raised the firm's price target on Bausch + Lomb to $15 from $13 and keeps a Neutral rating on the shares. The firm adjusted targets in medical technology as part of a Q2 earnings preview.
Barclays
Matt Miksic
Equal Weight
downgrade
$19 -> $16
2025-06-09
Reason
Barclays
Matt Miksic
Price Target
$19 -> $16
2025-06-09
downgrade
Equal Weight
Reason
Barclays analyst Matt Miksic lowered the firm's price target on Bausch + Lomb to $16 from $19 and keeps an Equal Weight rating on the shares. The company confirmed at an investor conference that it will be able to offset its 25c tariff headwind, the analyst tells investors in a research note. The firm cut the price target but expects Bausch + Lomb to potentially trade higher in the near-term on this update.
RBC Capital
Douglas Miehm
Buy
Maintains
$18 → $17
2025-04-04
Reason
RBC Capital
Douglas Miehm
Price Target
$18 → $17
2025-04-04
Maintains
Buy
Reason
Stifel
Tom Stephan
Hold
Maintains
$17 → $15
2025-04-03
Reason
Stifel
Tom Stephan
Price Target
$17 → $15
2025-04-03
Maintains
Hold
Reason
Wells Fargo
Larry Biegelsen
Buy
to
Hold
Downgrades
$24 → $15
2025-03-28
Reason
Wells Fargo
Larry Biegelsen
Price Target
$24 → $15
2025-03-28
Downgrades
Buy
to
Hold
Reason
Wells Fargo downgraded Bausch + Lomb to Equal Weight from Overweight with a price target of $15, down from $24.
HC Wainwright & Co.
Yi Chen
Strong Buy
Maintains
$23 → $20
2025-02-21
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$23 → $20
2025-02-21
Maintains
Strong Buy
Reason
BofA lowered the firm's price target on Bausch + Lomb (BLCO) to $17 from $18 and keeps an Underperform rating on the shares. 2025 guidance, particularly EBITDA, likely disappointed investors even though B+L signaled lower expectations in early January, notes the analyst. The firm continues to believe the stock upside is limited until investors get more visibility into Bausch + Lomb's separation from Bausch Health (BHC), the analyst added.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Bausch + Lomb Corp (BLCO.N) is 19.60, compared to its 5-year average forward P/E of 21.56. For a more detailed relative valuation and DCF analysis to assess Bausch + Lomb Corp 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
21.56
Current PE
19.60
Overvalued PE
25.74
Undervalued PE
17.38

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
10.65
Current EV/EBITDA
10.42
Overvalued EV/EBITDA
11.43
Undervalued EV/EBITDA
9.86

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
1.30
Current PS
0.95
Overvalued PS
1.51
Undervalued PS
1.08

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

BLCO News & Events

Events Timeline

(ET)
2025-06-04
07:05:43
Bausch + Lomb launches Blink Nourish, Blink Boost eyedrops in U.S.
select
2025-05-21 (ET)
2025-05-21
07:01:12
Bausch + Lomb launches LUMIFY Preservative Free redness reliever eye drops in US
select
2025-05-07 (ET)
2025-05-07
07:54:50
Bausch + Lomb announces CE Mark approval for LuxLife
select
Sign Up For More Events
Sign Up For More Events

News

Preview
4.0
07-11NASDAQ.COM
BLCO Crosses Above Average Analyst Target

  • Stock Performance: Bausch + Lomb Corporation's shares have surpassed the average analyst 12-month target price of $14.08, currently trading at $14.20, prompting analysts to consider either downgrading their valuation or raising their target prices based on the company's performance.

  • Analyst Insights: The average target price is derived from 13 analysts, with a range from $11.00 to $18.00, indicating varied expectations and encouraging investors to evaluate whether the stock's current price reflects its true value or if it has become overvalued.

Preview
4.0
07-08Benzinga
Evercore ISI Group Maintains Outperform on Bausch & Lomb, Raises Price Target to $16

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, providing real-time intelligence to help them succeed in the stock market.

  • Community and Exclusivity: Joining Benzinga Pro connects users with over 10,000 serious traders and grants access to exclusive stories and insights from Benzinga reporters.

Preview
5.0
07-01Newsfilter
Bausch + Lomb Combines Patient Voices and New Survey Insights to Combat Persistent Misconceptions about Dry Eye

  • Campaign Launch: Bausch + Lomb has launched the "Eyes Tell the Story" campaign to raise awareness about dry eye through personal stories and survey data, encouraging sufferers to seek relief from their symptoms sooner.

  • Survey Findings: A recent survey revealed that many dry eye sufferers lack adequate knowledge about their condition, with a significant percentage misunderstanding treatment needs and timelines, highlighting the necessity for better education and proactive management.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Bausch + Lomb Corp (BLCO) stock price today?

The current price of BLCO is 14.18 USD — it has increased 1.5 % in the last trading day.

arrow icon

What is Bausch + Lomb Corp (BLCO)'s business?

Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.

arrow icon

What is the price predicton of BLCO Stock?

Wall Street analysts forecast BLCO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLCO is 13.38 USD with a low forecast of 11.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Bausch + Lomb Corp (BLCO)'s revenue for the last quarter?

Bausch + Lomb Corp revenue for the last quarter amounts to 1.14B USD, increased 3.46 % YoY.

arrow icon

What is Bausch + Lomb Corp (BLCO)'s earnings per share (EPS) for the last quarter?

Bausch + Lomb Corp. EPS for the last quarter amounts to -0.60 USD, increased 25.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Bausch + Lomb Corp (BLCO)'s fundamentals?

The market is revising Upward the revenue expectations for Bausch + Lomb Corporation (BLCO) for FY2025, with the revenue forecasts being adjusted by 0.63% over the past three months. During the same period, the stock price has changed by 17.68%.
arrow icon

How many employees does Bausch + Lomb Corp (BLCO). have?

Bausch + Lomb Corp (BLCO) has 13500 emplpoyees as of July 18 2025.

arrow icon

What is Bausch + Lomb Corp (BLCO) market cap?

Today BLCO has the market capitalization of 5.02B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free